William Blair, Charles River Labs and Market

William Blair cuts Charles River Labs stock rating to Market Perform
William Blair analysts downgraded shares of Charles River Laboratories International Inc. (NYSE:CRL) stock from Outperform to Market Perform. The decision comes amid growing concerns about the company's near-term prospects,
Charles River Labs downgraded at William Blair on less early-stage R&D spending
William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.
Charles River downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working
Charles River Laboratories International’s (CRL) “Neutral” Rating Reiterated at UBS Group
UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They currently have a $185.
Charles River Labs downgraded to neutral by UBS
UBS has downgraded Charles River Laboratories (NYSE:CRL) to neutral from buy, citing concerns about decelerating sales growth. The investment bank said its view is supported not only by the company's recent financial results and outlook,
Hold Rating for Charles River Labs Amid Supply Chain Challenges and Mitigation Strategies
Mizuho Securities analyst Ann Hynes has maintained their neutral stance on CRL stock, giving a Hold rating yesterday.Stay Ahead of the
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors
This was the stock's third consecutive day of losses.
RiverWater Partners Sustainable Value Strategy Trimmed its Investment in Charles River Laboratories (CRL)
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...
What Analysts Are Saying About Charles River Stock
Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...
Morningstar2d
Charles River Laboratories International Inc CRL
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
What Makes Charles River Labs (CRL) an Investment Bet?
Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...
TMCnet2d
Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences
Apollo for Biologics: Provides a centralized platform to submit sample submission forms, track samples, and exchange documents all in one place, ensuring accuracy and saving time.
GlobalData on MSN6d
Charles River and Akron link to integrate cytokines into cell therapy
The integration enables closed system processing, a significant step in automating platforms and protocols for cell therapies ...
Hosted on MSN1d
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
Charles River Laboratories International, Inc. CRL has introduced Apollo for CRADL (Charles River Accelerator and Development Lab), a secure cloud-based platform that enhances leading vivarium rental ...